Physician profile
John Sharma
NPI 1114131778
$2,411.36
in general payments reported to CMS, 2019-2025
30 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.90 · 2022: $440 · 2023: $609 · 2024: $938 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,871.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $583.09 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $469.87 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $188.76 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.85 | 2021-2025 | Jardiance |
| Exact Sciences Corporation | $122.15 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $97.35 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $84.84 | 2021-2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $61.06 | 2022 | |
| Alkermes, INC. | $58.38 | 2023-2025 | Aristada, Lybalvi |
| Abbott Laboratories | $54.56 | 2022-2024 | Freestyle Libre 3 |
| Pfizer INC. | $54.52 | 2022-2023 | |
| Amgen INC. | $54.32 | 2021-2024 | Prolia, Evenity, Repatha |
| Phathom Pharmaceuticals, INC. | $47.34 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.22 | 2024 | Xifaxan |
| Dexcom, INC. | $37.43 | 2024 | Dexcom G6 Transmitter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $36.69 | 2024-2025 | Uzedy, Austedo Xr |
| Glaxosmithkline, LLC. | $32.44 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Tandem Diabetes Care, INC. | $32.28 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Biohaven Pharmaceutical Holding Company LTD. | $31.21 | 2022 | |
| Axsome Therapeutics, INC. | $29.88 | 2024 | Auvelity |
| Xeris Pharmaceuticals, INC. | $23.93 | 2023 | Gvoke Hypopen |
| Lundbeck LLC | $20.21 | 2024 | Rexulti |
| Nestle Healthcare Nutrition INC. | $17.72 | 2022 | |
| Sumitomo Pharma America, INC. | $17.34 | 2023 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $16.59 | 2021 | |
| Ironshore Pharmaceuticals INC. | $15.63 | 2022 | |
| Medtronic, INC. | $14.62 | 2024 | Kyphon Express II Kyphopak Tray |
| Aimmune Therapeutics, INC. | $13.92 | 2025 | Zenpep |
| Amarin Pharma, INC. | $12.83 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.